贝伐单抗治疗卵巢癌的临床研究进展

被引：15

作者：

陈乃兴 ^{[1
,2
]}

金科涛 ^{[2
,3
]}

机构：

[1] 浙江富阳市场口人民医院

[2] 温州医学院附属诸暨医院肝胆外科

[3] 浙江大学医学院附属第一医院肿瘤外科

来源：

中国药房 | 2012年 / 23卷 / 10期

关键词：

贝伐单抗; 卵巢癌; 分子靶向治疗; 血管内皮生长因子;

D O I：

暂无

中图分类号：

R737.31 [卵巢肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

目的:为贝伐单抗治疗卵巢癌提供理论基础。方法:通过归纳总结近年来国内、外相关文献,主要分析贝伐单抗在卵巢癌治疗中的疗效和不良反应及其防治措施。结果:多项临床试验的结果已经显示了贝伐单抗在卵巢癌治疗中的临床价值。结论:贝伐单抗将成为卵巢癌的治疗选择之一。

引用

页码：934 / 936

页数：3

共 10 条

[1]

反应停对人癌裸鼠肿瘤及新血管形成的影响 [J].

徐华 ;

赵凤琴 ;

任亮 ;

康红钰 .

中国药房, 2007, (34) :2664-2666

[2]

分子和抗体靶向抗肿瘤药的研究进展 [J].

刘德忠 ;

张石革 .

中国药房, 2007, (26) :2067-2068

[3]

Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?.[J].Ketao Jin;Yanping Shen;Kuifeng He;Zhenzhen Xu;Guangliang Li;Lisong Teng.Clinical and Translational Oncology.2010, 8

[4]

Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment [J].

Teng, Li-Song ;

Jin, Ke-Tao ;

He, Kui-Feng ;

Wang, Hao-Hao ;

Cao, Jiang ;

Yu, De-Cao .

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2010, 73 (06) :281-288

[5]

Bevacizumab toxicities and their management in ovarian cancer [J].

Randall, Leslie M. ;

Monk, Bradley J. .

GYNECOLOGIC ONCOLOGY, 2010, 117 (03) :497-504

[6]

Trials With Impact on Clinical Management: First Line.[J].Michael A. Bookman.International Journal of Gynecological Cancer.2009, 11 S

[7]

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[8]

Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization.[J].Dai Fukumura;Rakesh K. Jain.Microvascular Research.2007, 2

[9]

Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension [J].

Izzedine, Hassane ;

Rixe, Olivier ;

Billemont, Bertrand ;

Baumelou, Alain ;

Deray, Gilbert .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) :203-218

[10]

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis [J].

Zhu, Xiaolei ;

Wu, Shenhong ;

Dahut, William L. ;

Parikh, Chirag R. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (02) :186-193

← 1 →